Every 10-Q that Omega Flex (OFLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OFLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OFLX filings page.
Omega Flex, Inc. reported lower results for the quarter and six months ended June 30, 2026. Net sales were $24.1 million for the quarter and $47.2 million year-to-date, both modestly below 2025 levels. Gross margin contracted to 55.0% in Q2 and 55.8% for the half-year, down from 60.4%, mainly from higher raw material, freight and tariff costs.
Operating profit fell to $3.1 million in Q2 and $5.4 million for six months, with year-to-date operating profit down 38.9%. Net income attributable to Omega Flex was $2.7 million for Q2 and $4.8 million for six months. Operating cash flow declined to $2.4 million. The company ended the period with $47.9 million in cash, no borrowings on a $15 million credit facility, and paid $6.9 million in dividends. Management highlights ongoing investment in MediTrac® corrugated medical tubing and notes a significant customer accounting for over 10% of sales and receivables.
Omega Flex, Inc. reported weaker results for the quarter ended March 31, 2026. Net sales were $23.1 million, down slightly from $23.3 million a year earlier, but profitability fell more sharply as costs rose.
Gross margin declined to 56.7% from 60.3%, and operating profit dropped to $2.3 million from $4.1 million, reflecting higher raw material (including tariffs), selling, and engineering expenses. Net income attributable to Omega Flex decreased to $2.1 million, or $0.21 per share, compared with $3.6 million, or $0.35 per share, in the prior-year quarter.
The company remains highly liquid, with $49.8 million of cash and cash equivalents and no borrowings on its $15 million revolving credit facility as of March 31, 2026. Omega Flex continued its regular dividend, declaring $0.34 per share, or $3.4 million in total.
Omega Flex, Inc. (OFLX) reported Q3 2025 results showing softer demand and higher costs. Net sales were $24.234 million versus $24.880 million a year ago, while gross margin eased to 60.2% from 61.7% as staffing-related costs and tariffs weighed on profitability. Operating profit fell to $4.185 million from $5.468 million, and EPS was $0.37 versus $0.46.
For the first nine months of 2025, sales were $73.089 million compared to $74.716 million, with operating profit of $12.957 million versus $15.809 million and EPS of $1.13 versus $1.32. The company ended the quarter with $49.368 million in cash, no debt, and an undrawn $15 million credit facility. Quarterly dividends of $0.34 per share continued, with $10.297 million declared year-to-date.
Management cited lower unit volumes, particularly tied to a challenged residential housing market, and higher engineering and administrative expenses. Product liability reserves within insurance retentions declined to $322,000, and the aggregate maximum exposure for open claims within retentions was estimated at approximately $4.207 million.
Omega Flex (NASDAQ: OFLX) filed its Q2-25 Form 10-Q. Net sales grew 3.7 % to $25.5 m, but a 140 bp slip in gross margin (60.4 %) and higher selling, G&A and engineering spend cut operating profit 10.6 % to $4.7 m. Net income attributable to OFLX declined 7.6 % to $4.2 m, and EPS fell to $0.41 from $0.45.
First-half trends were softer. Six-month sales eased 2 % to $48.9 m; operating profit dropped 15.2 % to $8.8 m and EPS slid 10 c to $0.77. Engineering expense rose 29 % YoY as the company invested in product development.
Balance sheet remains solid. Cash and equivalents total $50.7 m (-$1.0 m YTD) with no debt and a $15 m unused revolver. Working-capital metrics are stable; inventory at $14.5 m and A/R allowances improved. Operating cash flow was $7.0 m, essentially flat YoY, funding $1.0 m of capex and $6.9 m in dividends ($0.68 per share YTD, $0.34 declared for Q2).
Guidance & risks. Management cites weaker housing starts and higher engineering spend as headwinds. Litigation reserves fell to $0.5 m, but product-liability exposure remains; aggregate potential within insurance retentions is estimated at $5.0 m.